Clik here to view.
Insurance upstart Clover Health launches new business selling its tech,...
(This story is from our new Health Tech newsletter. If you’d like to sign up, just click here.) The Medicare-focused health insurer Clover Health has launched a new venture to sell its technology...
View ArticleImmunovant postpones batoclimab readouts, maps path forward for second FcRn drug
Immunovant has reshuffled plans for two of its anti-FcRn antibody drugs. The company has delayed clinical readouts by several months for its late-stage FcRn inhibitor, called batoclimab, on the heels...
View ArticleBridgeBio touts additional ATTR-CM drug data in new analyses of Phase 3 trial
BridgeBio released additional analyses of its Phase 3 study of acoramidis in ATTR-CM on Wednesday, spotlighting the link between serum transthyretin (TTR) levels and the drug’s long-term efficacy in...
View ArticleCinRx raises $73M to create more biotechs, further support obesity drug...
CinRx Pharma, the creator of biotechs like CinCor, which was acquired by AstraZeneca, raised another $73 million to support its current portfolio and launch startups to develop in-licensed drugs. The...
View ArticleExclusive: Plenful nabs $17M to automate pharmacy operations
(This story is from our new Health Tech newsletter. If you’d like to sign up, just click here.) Plenful, a startup that wants to free pharmacists from burdensome back-office tasks, has raised $17...
View ArticleCompugen, Nxera disclose milestone payments; Insmed aims for $650M offering
Plus, news about Celcuity and Weave Bio: Compugen bags $5M milestone from AstraZeneca: The payment was triggered after the first lung cancer patient was dosed in a Phase 3 trial of AstraZeneca’s...
View ArticleFlush with cash, Novo Nordisk Foundation now plans to reinvest some GLP-1...
The Novo Nordisk Foundation, the majority owner of Novo Nordisk, plans to put more money into regenerative medicines, including stem cells and cell therapies for a wide range of diseases. The decision,...
View ArticleNovartis ends development of KRAS drug, citing 'increasing options available'
Novartis will stop developing a KRAS lung cancer drug that had made it to Phase 3 testing, a spokesperson confirmed to Endpoints News on Thursday. The experimental medicine, known as JDQ443 or...
View Article#ASCO24: The biopharma news we’re paying attention to
More than 40,000 people are expected to congregate in Chicago this week for the American Society of Clinical Oncology’s annual meeting, and an estimated 5,800 abstracts from drug companies and...
View ArticleClik here to view.
Doctors who endorse drugs on social media are often compensated, JAMA study...
Physicians who posted endorsements of drugs on social media often received cash payments from industry, and in some cases didn’t disclose that they had been compensated, a team of researchers found in...
View ArticleAlmac’s 2023 revenue bump; France to invest in easing greenhouse gas impact
Welcome to Endpoints News’ manufacturing briefs, where we bring you essential news on new builds, collaborations, recalls and more. Almac reported a 14% increase in its revenue last year, reaching £958...
View ArticleUK won’t order Grail’s cancer test for 1M people this year, a setback for...
The UK’s National Health Service will wait until 2026 before deciding whether to roll out Grail’s cancer test to one million people, a setback for Illumina and its plan to divest the diagnostics...
View ArticleFDA to begin restructuring its inspection office in October
The FDA received an official go-ahead from HHS on Thursday, setting into motion its planned reorganization of its inspection operations around the globe, with an extra focus on facility inspections,...
View ArticleBristol Myers' CAR-T therapy Breyanzi adds new approval in mantle cell lymphoma
Bristol Myers Squibb’s CAR-T therapy Breyanzi scored its third approval over the last several months, this time in the third-line setting for adults with relapsed or refractory mantle cell lymphoma, a...
View ArticleLab group sues FDA over final rule regulating laboratory-developed tests
The American Clinical Laboratory Association is arguing in a new lawsuit that the FDA has overstepped its authority by bringing laboratory-developed tests (LDTs) under its purview, the first major...
View ArticleClik here to view.
Novo Nordisk mounts legal campaign against companies marketing compounded...
Novo Nordisk is ramping up its legal campaign against medical spas, pharmacies and clinics marketing compounded versions of its popular weight loss and diabetes drugs. The Danish pharma filed nine new...
View ArticleSummit Therapeutics' stock soars as biotech says its cancer drug beat...
Hours before America’s biggest cancer conference starts in Chicago, a small biotech may have stolen the show, touting late-stage results in a Thursday afternoon press release that added over $5 billion...
View ArticleGilead’s blockbuster ADC Trodelvy fails bladder cancer confirmatory study
Gilead on Thursday disclosed that Trodelvy, the antibody-drug conjugate that is a key part of the drugmaker’s oncology business, failed a Phase 3 study after it didn’t show an improvement in patient...
View ArticleFDA delays decision on Sanofi and Regeneron's Dupixent in COPD, EMA...
Sanofi and Regeneron will have to wait three more months for a major FDA decision on expanding Dupixent’s label, the companies disclosed Friday morning. Meanwhile, European authorities have recommended...
View ArticleUltragenyx touts Phase 3 win for gene therapy in rare glycogen storage disorder
Ultragenyx’s one-time gene therapy has hit the primary endpoint in a registrational test in a rare glycogen storage disorder, triggering company plans to file with regulatory authorities next year. The...
View Article